Alnylam Pharmaceuticals | ALNY - EPS Earnings Per Share


Alnylam Pharmaceuticals reported $1.99 in EPS Earnings Per Share for its fiscal quarter ending in March of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2025 1.97 2.90 Oct/29
FY2026Q2 Jun/2026 1.61 0.32 Jul/30
FY2026Q1 Mar/2026 1.99 0.99 -0.01 Apr/30
FY2025Q4 Dec/2025 1.25 1.27 0.06 Feb/12
FY2025Q3 Sep/2025 2.90 0.27 -0.50 Oct/30




Eps Change Date
Acadia Pharmaceuticals USD 0.02 1.58 Mar/2026
Agios Pharmaceuticals USD -1.69 0.17 Mar/2026
Alnylam Pharmaceuticals USD 1.99 0.74 Mar/2026
Amgen USD 5.15 0.14 Mar/2026
Arrowhead Research USD -0.93 1.15 Mar/2026
BioCryst Pharmaceuticals USD 1.17 1.1 Dec/2025
BioMarin Pharmaceutical USD 0.76 0.3 Mar/2026
Incyte USD 1.81 0.01 Mar/2026
Ionis Pharmaceuticals USD -0.56 0.85 Mar/2026
Moderna USD -3.4 1.29 Mar/2026
Neurocrine Biosciences USD 1.94 0.06 Mar/2026
Novartis USD 1.99 0.45 Mar/2026
PTC Therapeutics USD -0.03 1.64 Mar/2026
Regeneron Pharmaceuticals USD 9.47 1.97 Mar/2026
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Sanofi EUR 2.17 2.84 Mar/2026
Sarepta Therapeutics USD 3.16 6.74 Mar/2026
Takeda JPY -15.56 81.3 Mar/2026
Tectonic Therapeutic USD -1.34 0.32 Mar/2026
Ultragenyx Pharmaceutical USD -1.84 0.55 Mar/2026
Vertex Pharmaceuticals USD 4.47 0.56 Mar/2026
Xencor USD -1.71 1.62 Mar/2026